Table 1.
Demographic data and clinical features of the urosepsis and the control groups.
| Urosepsis (n = 36) |
Control (n = 76) |
χ 2/t | P value | |
|---|---|---|---|---|
| Age (years) | 43.6 ± 12.5 | 57.3 ± 19.3 | −3.886 | <0.001 |
| Gender (male/female, %) | 17/19 (47%/53%) | 45/31 (59%/41%) | 1.421 | 0.233 |
| APACHE II score | 20.3 ± 5.6 | 21.8 ± 6.1 | −1.247 | 0.215 |
| SOFA score | 5.8 ± 1.9 | 5.1 ± 2.2 | 1.640 | 0.104 |
| HLA-DR (%) | 56.47 ± 21.63 | 49.85 ± 24.47 | 1.386 | 0.168 |
| Combination diseases | 1.02 ± 0.84 | 2.36 ± 1.44 | −5.174 | <0.001 |
| Time before being sent to ICU (hours) | 9.2 ± 6.6 | 7.2 ± 4.9 | 1.798 | 0.075 |
| Organ dysfunction time (hours) | 4.7 ± 2.4 | 7.2 ± 4.5 | −3.124 | 0.002 |
| WBC count (×109/L) | 6.3 ± 5.5 | 14.7 ± 4.8 | −8.249 | <0.001 |
| PLT count (×109/L) | 83.2 ± 34.6 | 138.9 ± 45.1 | −6.548 | <0.001 |
| Serum creatinine (μmol/L) | 125.9 ± 49.8 | 121.2 ± 56.4 | 0.427 | 0.670 |
| Bilirubin (μmol/L) | 15.9 ± 3.8 | 16.4 ± 3.2 | −0.726 | 0.469 |
| Mean arterial pressure (mmHg) | 92.8 ± 19.2 | 99.3 ± 17.7 | −2.038 | 0.053 |
| Oxygenation index | 214.1 ± 45.3 | 208.3 ± 56.5 | 0.539 | 0.591 |
| PCT (ng/mL) | 129.3 ± 40.8 | 41.2 ± 38.4 | 11.114 | <0.001 |
| ICU stay (days) | 11.6 ± 5.5 | 14.8 ± 7.1 | −2.384 | 0.019 |
| Total hospitalization (days) | 16.2 ± 6.9 | 18.1 ± 9.2 | −1.100 | 0.274 |
| Mechanical ventilation | 20 (56%) | 53 (70%) | 2.165 | 0.141 |
| Vasoactive drugs use | 17 (47%) | 29 (38%) | 0.829 | 0.362 |
| CRRT | 10 (28%) | 21 (28%) | 0.000 | 0.987 |
| Extracorporeal liver assist device (artificial liver) | 2 (6%) | 5 (7%) | 0.044 | 0.834 |
| Positive blood cultures | 27 (75%) | 23 (30%) | 19.783 | <0.001 |
| 28-day mortality | 2 (6%) | 28 (37%) | 12.193 | <0.001 |
| 90-day mortality | 2 (6%) | 32 (42%) | 15.436 | <0.001 |
APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; ICU, intensive care unit; WBC, white blood cell; PLT, platelet; PCT, procalcitonin; CRRT, continuous renal replacement therapy.